Event rates (per 100 person-years) within 2-year follow-up by treatment at baseline
| Treatment at baseline | Outcome | |||||
| All-cause mortality | Non-haemorrhagic stroke/SE | Major bleeding | ||||
| Events | Rate (95% CI) | Events | Rate (95% CI) | Events | Rate (95% CI) | |
| FXaI | 536 | 3.7 (3.4 to 4.0) | 112 | 0.8 (0.6 to 0.9) | 152 | 1.0 (0.9 to 1.2) |
| DTI | 130 | 3.3 (2.8 to 3.9) | 34 | 0.9 (0.6 to 1.2) | 29 | 0.7 (0.5 to 1.1) |
| Any NOAC | 666 | 3.6 (3.3 to 3.9) | 146 | 0.8 (0.7 to 0.9) | 181 | 1.0 (0.9 to 1.1) |
| VKA | 773 | 4.8 (4.5 to 5.2) | 153 | 1.0 (0.8 to 1.1) | 223 | 1.4 (1.2 to 1.6) |
| Any OAC | 1439 | 4.1 (3.9 to 4.4) | 299 | 0.9 (0.8 to 1.0) | 404 | 1.2 (1.1 to 1.3) |
| No OAC | 737 | 5.6 (5.2 to 6.0) | 168 | 1.3 (1.1 to 1.5) | 102 | 0.8 (0.6 to 1.0) |
DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; SE, systemic embolism; VKA, vitamin K antagonist.